Clinical Trial Update: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bimagrumab and tirzepatide, alone or in combination, in adults with obesity or overweight with Type 2 diabetes, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Bimagrumab (bimagrumab)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 2 | Status: WITHDRAWN